158 related articles for article (PubMed ID: 30237722)
1. Arterial elasticity as a risk factor for early cardiovascular disease among testicular cancer survivors treated with platinum-based chemotherapy: a cross-sectional pilot study.
Blaes AH; Mulrooney DA; Vogel RI; Solovey A; Hebbel R; Peterson BA; Neglia JP; Biewen C; Konety SH; Duprez DA
Vasc Health Risk Manag; 2018; 14():205-211. PubMed ID: 30237722
[TBL] [Abstract][Full Text] [Related]
2. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy.
Stelwagen J; Lubberts S; Steggink LC; Steursma G; Kruyt LM; Donkerbroek JW; van Roon AM; van Gessel AI; van de Zande SC; Meijer C; Gräfin Zu Eulenburg CH; Oosting SF; Nuver J; Walenkamp AME; Jan de Jong I; Lefrandt JD; Gietema JA
Br J Cancer; 2020 Nov; 123(11):1599-1607. PubMed ID: 32921790
[TBL] [Abstract][Full Text] [Related]
3. Testicular cancer survivorship: research strategies and recommendations.
Travis LB; Beard C; Allan JM; Dahl AA; Feldman DR; Oldenburg J; Daugaard G; Kelly JL; Dolan ME; Hannigan R; Constine LS; Oeffinger KC; Okunieff P; Armstrong G; Wiljer D; Miller RC; Gietema JA; van Leeuwen FE; Williams JP; Nichols CR; Einhorn LH; Fossa SD
J Natl Cancer Inst; 2010 Aug; 102(15):1114-30. PubMed ID: 20585105
[TBL] [Abstract][Full Text] [Related]
4. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy.
Lubberts S; Boer H; Altena R; Meijer C; van Roon AM; Zwart N; Oosting SF; Kamphuisen PW; Nuver J; Smit AJ; Mulder AB; Lefrandt JD; Gietema JA
Eur J Cancer; 2016 Aug; 63():180-8. PubMed ID: 27322917
[TBL] [Abstract][Full Text] [Related]
5. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR; Ardeshir-Rouhani-Fard S; Monahan P; Sesso HD; Fung C; Williams AM; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Zaid MA; Lipshultz SE; Einhorn LH; Oeffinger KC; Travis LB; Fossa SD;
Clin Genitourin Cancer; 2018 Aug; 16(4):e761-e769. PubMed ID: 29534941
[TBL] [Abstract][Full Text] [Related]
6. Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors.
Boer H; Westerink NL; Altena R; Nuver J; Dijck-Brouwer DAJ; van Faassen M; Klont F; Kema IP; Lefrandt JD; Zwart N; Boezen HM; Smit AJ; Meijer C; Gietema JA
Eur J Cancer; 2016 Feb; 54():104-111. PubMed ID: 26751392
[TBL] [Abstract][Full Text] [Related]
7. Early development of the metabolic syndrome after chemotherapy for testicular cancer.
de Haas EC; Altena R; Boezen HM; Zwart N; Smit AJ; Bakker SJ; van Roon AM; Postma A; Wolffenbuttel BH; Hoekstra HJ; van Leeuwen FE; Sleijfer DT; Gietema JA
Ann Oncol; 2013 Mar; 24(3):749-55. PubMed ID: 23131388
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.
Haugnes HS; Wethal T; Aass N; Dahl O; Klepp O; Langberg CW; Wilsgaard T; Bremnes RM; Fosså SD
J Clin Oncol; 2010 Oct; 28(30):4649-57. PubMed ID: 20855830
[TBL] [Abstract][Full Text] [Related]
9. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M; Dinh PC; Monahan PO; Fung C; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Sesso HD; Huddart R; Mushiroda T; Kubo M; Dolan ME; Einhorn LH; Fossa SD; Travis LB;
J Natl Compr Canc Netw; 2019 May; 17(5):459-468. PubMed ID: 31085753
[TBL] [Abstract][Full Text] [Related]
10. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.
Nuver J; Smit AJ; van der Meer J; van den Berg MP; van der Graaf WT; Meinardi MT; Sleijfer DT; Hoekstra HJ; van Gessel AI; van Roon AM; Gietema JA
J Clin Oncol; 2005 Dec; 23(36):9130-7. PubMed ID: 16301596
[TBL] [Abstract][Full Text] [Related]
11. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
12. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy.
Khanal N; Ahmed SS; Kalra M; Miller TJ; Brames MJ; Stump TE; Monahan P; Hanna NH; Einhorn LH
Support Care Cancer; 2020 Jul; 28(7):3165-3170. PubMed ID: 31707501
[TBL] [Abstract][Full Text] [Related]
13. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors.
Willemse PM; Burggraaf J; Hamdy NA; Weijl NI; Vossen CY; van Wulften L; van Steijn-van Tol AQ; Rosendaal FR; Osanto S
Br J Cancer; 2013 Jul; 109(1):60-7. PubMed ID: 23660945
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study.
Ykema BLM; Bisseling TM; Spaander MCW; Moons LMG; van der Biessen-van Beek D; Saveur L; Kerst M; Mulder SF; de Wit R; Zweers D; Meijer GA; Beijnen JH; Lansdorp-Vogelaar I; van Leeuwen FE; Snaebjornsson P; van Leerdam ME
BMC Gastroenterol; 2021 Feb; 21(1):67. PubMed ID: 33579196
[TBL] [Abstract][Full Text] [Related]
16. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors.
Haugnes HS; Aass N; Fosså SD; Dahl O; Klepp O; Wist EA; Wilsgaard T; Bremnes RM
J Cancer Surviv; 2008 Sep; 2(3):128-37. PubMed ID: 18792787
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk in long-term survivors of testicular cancer.
Vaughn DJ; Palmer SC; Carver JR; Jacobs LA; Mohler ER
Cancer; 2008 May; 112(9):1949-53. PubMed ID: 18338810
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial.
Marlatt KL; Steinberger J; Rudser KD; Dengel DR; Sadak KT; Lee JL; Blaes AH; Duprez DA; Perkins JL; Ross JA; Kelly AS
J Adolesc Young Adult Oncol; 2019 Aug; 8(4):442-450. PubMed ID: 28853979
[No Abstract] [Full Text] [Related]
19. Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial.
Adams SC; DeLorey DS; Davenport MH; Stickland MK; Fairey AS; North S; Szczotka A; Courneya KS
Cancer; 2017 Oct; 123(20):4057-4065. PubMed ID: 28708930
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum-based chemotherapy.
Breekveldt ECH; Ykema BLM; Bisseling TM; Moons LMG; Spaander MCW; Huibregtse IL; van der Biessen-van Beek DTJ; Mulder SF; Saveur L; Kerst JM; Zweers D; Suelmann BBM; de Wit R; Reijm A; van Baalen S; Butterly LF; Hisey WM; Robinson CM; van Vuuren AJ; Carvalho B; Lansdorp-Vogelaar I; Schaapveld M; van Leeuwen FE; Snaebjornsson P; van Leerdam ME
Int J Cancer; 2024 Apr; 154(8):1474-1483. PubMed ID: 38151749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
